Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Cash & Equivalents (2020 - 2025)

SAB Biotherapeutics (SABS) has disclosed Cash & Equivalents for 6 consecutive years, with $10.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 18.03% year-over-year to $10.5 million, compared with a TTM value of $10.5 million through Dec 2025, up 18.03%, and an annual FY2025 reading of $10.5 million, up 18.03% over the prior year.
  • Cash & Equivalents was $10.5 million for Q4 2025 at SAB Biotherapeutics, down from $29.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $56.6 million in Q4 2023 and bottomed at $2.4 million in Q3 2023.
  • Average Cash & Equivalents over 5 years is $15.8 million, with a median of $11.9 million recorded in 2021.
  • Peak annual rise in Cash & Equivalents hit 279.31% in 2024, while the deepest fall reached 84.27% in 2024.
  • Year by year, Cash & Equivalents stood at $33.2 million in 2021, then crashed by 54.69% to $15.0 million in 2022, then skyrocketed by 275.93% to $56.6 million in 2023, then plummeted by 84.27% to $8.9 million in 2024, then rose by 18.03% to $10.5 million in 2025.
  • Business Quant data shows Cash & Equivalents for SABS at $10.5 million in Q4 2025, $29.4 million in Q3 2025, and $3.7 million in Q2 2025.